RFL
Fiscal year ends July Quarters are offset from the calendar — Q1 is Aug–Oct

Rafael Holdings, Inc. is a clinical-stage biotechnology company that develops pharmaceuticals and holds interests in companies developing pharmaceuticals and medical devices. Its lead candidate is Trappsol® Cyclo™, a cyclodextrin-based product in Phase 3 clinical trials for Niemann-Pick Disease Type C1. The company holds a majority interest in LipoMedix Pharmaceuticals, a clinical-stage developer of liposome-based cancer therapies, and Cornerstone Pharmaceuticals, a cancer metabolism therapeutics company. Rafael Medical Devices, an orthopedic-focused subsidiary, develops instruments for minimally invasive surgeries, including the FDA-cleared VECTR System for ligament or fascia release. Day Three Labs utilizes the Unlokt™ technology to assist third-party manufacturers in product development. The company also maintains a holding in Barer Institute, a cancer research entity, and Farber Partners, which holds licenses for serine hydroxymethyltransferase inhibitor programs. Rafael Holdings serves patients with rare genetic disorders and cancer, with operations primarily in the United States and Israel.

Summarised from the company's own disclosures, fiscal year ended Oct 2025

Industry Biotechnology Homepage rafaelholdings.com
Sector Healthcare IR page rafaelholdings.irpass.com/profiles/investor
Tags
rare diseases, oncology, cyclodextrin, liposome delivery, cancer metabolism, orthopedic devices, minimally invasive surgery, cannabinoid manufacturing, clinical trials, Trappsol® Cyclo™, LipoMedix Pharmaceuticals, Barer Institute, Cornerstone Pharmaceuticals, Rafael Medical Devices, Day Three Labs, Unlokt™, Vectr System, Farber Partners, Cyclo Therapeutics, Forme Therapeutics, RP Finance
Press page —

Metrics

Valuation  
Market cap $ 68.632M
Market cap (USD) $ 68.632M
P/E -1.27
PEG —
P/BV 0.91
P/S —
P/OCF -3.63
P/FCF -3.63
Dividend yield —
Turnover / mcap —
Returns  
ROE -34.6%
ROI -32.3%
ROIC -23.2%
Profit margin -101,733.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 2
Quality score -76.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 30K 637K 279K 410K 3.971M 4.91M 4.931M 4.371M 5.618M
Net profit -30.52M -34.41M -1.876M -140.547M -24.766M -10.415M -4.693M -11.649M 138K
Free cash flow -18.928M -7.945M -10.886M -26.081M -15.807M -5.2M -3.531M -2.525M -3.443M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 1.73 1.44 2.09 1.93 51.05 14.37 28.75 9.19 —
Price performance 12m 0.2 -0.31 0.08 -0.96 2.55 -0.5 2.13 — —

Filed figures

Figure Jul 2017 Jul 2018 Jul 2019 Jul 2020 Jul 2021 Jul 2022 Jul 2023 Jul 2024 Jul 2025 Jul 2026
Balance sheet detail
Trade receivables (USD) 264,000 287,000 450,000 267,000 235,000 157,000 213,000 426,000 627,000 444,000
↳ YoY growth +8.7% +56.8% -40.7% -12.0% -33.2% +35.7% +100.0% +47.2% -29.2%
↳ 5y CAGR -9.9% -5.8% -1.1% +18.6% +13.6%
Cash and deposits (USD) 11.8M 15.8M 12M 6.21M 12.9M 26.5M 21.5M 2.68M 52.8M 22.1M
Intangible assets (USD) — 324,000 — — — — — 1.85M 994,000 863,000
Cash flow detail
Operating cash flow (USD) -1.62M -1.82M -3.13M -4.67M -15.6M -26.1M -10.9M -7.8M -18.9M -30M
Purchases of property, plant and equipment (USD) -1.82M -710,000 -399,000 -534,000 -206,000 -2,000 — -143,000 -4,000 -3,000
Purchases of intangible assets (USD) — — — — — — — -35,000 -17,000 —
Change in receivables (cash effect) (USD) -7,000 -23,000 -285,000 87,000 -161,000 — — -150,000 -151,000 241,000
Change in inventories (cash effect) (USD) — — — — — — — — -11,000 -96,000
Change in payables (cash effect) (USD) 50,000 -35,000 533,000 713,000 164,000 52,000 -827,000 -146,000 — —
Income taxes paid (cash effect) (USD) -63,000 — — — — — — — — —
Share-based compensation (USD) — 51,000 — 684,000 6.63M -917,000 2.19M 2.3M 2.12M 1.39M
Operating cash flow before change in receivables (USD) -1.62M -1.79M -2.85M -4.75M -15.4M — — -7.65M -18.8M -30.2M
Free cash flow (OCF - PPE - intangibles) (USD) -3.44M -2.53M -3.53M -5.2M -15.8M -26.1M — -7.98M -18.9M -30M
Income detail
Research and development expense (USD) — 995,000 1.03M 2.39M 4.91M 8.74M 6.31M 4.17M 12.8M 24.3M
↳ 5y CAGR +44.7% +32.3% +39.9% +37.7%
Total comprehensive income (USD) 2.27M -10.3M -4.63M -10.8M -24.8M -125M -2.55M -64.6M -30.3M -27.7M
Comprehensive income to owners (USD) 2.27M -10.5M -4.45M -10.8M -24.8M -125M -2.21M -34M -30.2M -29.4M
Provision for credit losses (USD) — — 122,000 96,000 193,000 4,000 -1.2M -1.89M — -58,000
Credit cost ratio (credit losses / average receivables) (%) — — 33.1% 26.8% 76.9% 2.0% 645.9% 591.9% — 10.8%
Reported Oct 15, 2018 Oct 15, 2018 Oct 4, 2019 Oct 18, 2021 Oct 18, 2021 Oct 30, 2023 Nov 7, 2024 Oct 29, 2025 Oct 29, 2025 Oct 29, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Rafael Holdings, Inc. — Regulation FD Bull 0 Bear 0 Routine

From November 9, 2026, the slide presentation (the “Presentation”) attached hereto as Exhibit 99.1 will be available on the Registrant’s website at the following link: https://rafaelholdings.irpass.com/.

The Registrant is furnishing the information contained in this Report, including Exhibit 99.1, pursuant to Item 7.01 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC or incorporated by reference into any other filing with the SEC. In addition, the Presentation contains statements intended as “forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in the Presentation.

| NDA supported by the Phase 3 TransportNPC_™_ study, data from earlier clinical studies, and an overall survival analysis versus external registry controlsRemibetadex has received Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA; approval would make remibetadex eligible for a Rare Pediatric Disease Priority Review VoucherUnited States Adopted Names (USAN) Council assigns nonproprietary name "remibetadex" to Trappsol_®_ Cyclo_™_NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of remibetadex (Trappsol® Cyclo™, previously identified as intravenous hydroxypropyl-β-cyclodextrin), for the proposed indication of the treatment of the neurovisceral manifestations of Niemann-Pick Disease Type C (NPC) in adult and pediatric patients from birth. NPC is a rare, fatal and progressive genetic disorder for which there is no known cure. The Company also announced that the United States Adopted Names (USAN) Council has assigned the nonproprietary name "remibetadex" to the compound known until now as intravenous hydroxypropyl-β-cyclodextrin.Within 60 days of receiving the application, the FDA will determine whether the application is filed and, if filed, whether Priority Review will be granted. If the application is filed, the FDA will assign a Prescription Drug User Fee Act (PDUFA) target action date."This submission is an important milestone for Rafael Holdings and, most importantly, for patients living with NPC," said Howard Jonas, Chairman and Chief Executive Officer of Rafael Holdings. "I believe the totality of the data, including the Phase 3 trial results and the overall survival analysis, supports the potential of remibetadex for patients with limited treatment options. Pending FDA approval, we are excited to bring remibetadex to patients and families who urgently need new options to treat NPC."The NDA includes results from the global, double-blind, placebo-controlled Phase 3 TransportNPC™ study. Although the study did not achieve statistical significance on its primary endpoint, remibetadex showed a directionally favorable 64% relative slowing of disease progression compared with placebo (p=0.19) and in a prespecified analysis of patients receiving background therapy (approximately 83% of the study population), remibetadex showed a 71% relative slowing of disease progression (p=0.046). The NDA also includes data from earlier clinical studies and an overall survival analysis in which remibetadex was associated with an 85% reduction in the risk of mortality in patients with infantile-onset NPC compared with matched registry controls (p=0.044). Remibetadex was generally well tolerated, with no new safety signals observed, although serious adverse events occurred more frequently with remibetadex than with placebo (35.9% vs. 16.7%). Topline results from TransportNPC™ were reported on September 30, 2026."The remibetadex NDA is the culmination of more than 15 years of research and investment and, if approved, could help address a significant unmet need in a rare, and fatal disease," said Joshua Fine, Chief Operating Officer of Rafael Holdings. "With the data in the NDA and Orphan Drug, Fast Track and Rare Pediatric Disease designations in place, upon the FDA's filing of the NDA, we believe remibetadex is well positioned for review, and an approval would make it eligible for a Priority Review Voucher, a potential source of non-dilutive capital. With this important milestone completed, we are preparing for a potential commercial launch, and we look forward to working with the FDA as the regulatory review process advances. We are grateful to the investigators, patients, families and advocates who made this milestone possible."**About Remibetadex (Trappsol® Cyclo™) **Remibetadex is an investigational, intravenously administered therapy containing a proprietary formulation of hydroxypropyl-β-cyclodextrin and is being developed for the treatment of the neurovisceral manifestations of Niemann-Pick Disease Type C (NPC) in adult and pediatric patients from birth. Remibetadex is designed to mobilize cholesterol from late endosomes and lysosomes, facilitating the transport of accumulated cholesterol out of cells so it can be further processed and excreted. Remibetadex has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations by the FDA for the treatment of NPC.Remibetadex is an investigational product and has not been approved by the FDA or any other regulatory agency for any indication.**About Rafael Holdings, Inc. **Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is remibetadex (Trappsol® Cyclo™, previously identified as intravenous hydroxypropyl-β-cyclodextrin) for which we have completed a pivotal Phase 3 study in Niemann-Pick Disease Type C ("NPC") and submitted an NDA to the FDA in October 2026. NPC is a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.**Forward-Looking Statements **This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the FDA's review of our NDA, including whether the NDA will be accepted for filing or receive Priority Review; our eligibility for a Priority Review Voucher; our commercial preparations; plans regarding the further evaluation of clinical data; and the potential of our pipeline. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risk that the FDA may not accept for filing or approve an NDA for remibetadex based on the available data; the risk that we may not receive or be able to monetize a Priority Review Voucher; and those disclosed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2026, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.Contact: Barbara Ryan [email protected] (203) 274-2825 Primary Logo | | Oct 29, 2026 |

Copyright ©2026 Rafael Holdings, Inc. All rights reserved

Privacy

Resize Viewer - Reduce Resize Viewer - Expand [Close window](javascript:document.body.className=''; b2iCloseDownloadPage();)

News |

Investors

CONTACT US

Rafael Holdings

home Navigation

Investors News

**Investors

**

News====Search:

   PDF     Print     View AllRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update

NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026.

Fiscal 2026 and Recent Corporate Highlights

  • NDA submitted for remibetadex (Trappsol® Cyclo™). On October 28, 2026, Cyclo Therapeutics submitted a New Drug Application (NDA) to the FDA seeking approval of remibetadex for the treatment of Niemann-Pick Disease Type C. The NDA is supported by the Phase 3 TransportNPC™ study, completed in June 2026, which did not meet its primary endpoint in the overall population (p=0.19) but showed 71% slowing of disease progression in a prespecified analysis of patients receiving background miglustat and/or leucine therapy (p=0.046), and by an overall survival analysis versus matched registry controls. The NDA includes a request for a rare pediatric disease priority review voucher.
  • MIT license in Alzheimer's disease. In April 2026, Cyclo entered into an exclusive, worldwide license with the Massachusetts Institute of Technology for the use of hydroxypropyl-β-cyclodextrin in Alzheimer's disease.
  • LipoMedix. In June 2026, an investigator-initiated Phase II trial of Promitil® with radiotherapy in patients with cisplatin-ineligible head and neck cancer was launched in Israel.
  • Rafael Medical Devices. Continued the U.S. commercial build-out of the FDA-cleared VECTR™ System, including its regional distributor network.

Rafael Holdings, Inc. Fourth Quarter Fiscal Year 2026 Financial Results

As of July 31, 2026, we had cash and cash equivalents of $22.1 million.

For the three months ended July 31, 2026, we recorded a net loss attributable to Rafael Holdings of $9.2 million, or $0.18 per share, versus a net loss of $12.1 million, or $0.28 per share in the year ago period. The year over year decrease in net loss is largely attributable to a decrease in general and administrative expenses.

Research and development expenses were $7.5 million for each of the three months ended July 31, 2026 and 2025.

General and administrative expenses were $2.4 million for the three months ended July 31, 2026, compared to $5.5 million in the year ago period. The year over year decrease relates to a decrease in payroll, stock-based compensation expense and professional fees.

Rafael Holdings, Inc. Full Fiscal Year 2026 Financial Results

For the twelve months ended July 31, 2026, we recorded a net loss attributable to Rafael Holdings of $29.6 million, or $0.58 per share, versus a net loss of $30.5 million, or $1.04 per share in the year ago period. The year over year decrease in net loss reflects a $4.4 million gain on Cornerstone's settlements of accounts payable and convertible notes payable and the absence of prior-year unrealized losses on our investment in Cyclo, partially offset by higher research and development expenses following the consolidation of Cyclo Therapeutics in March 2025.

Research and development expenses were $24.3 million for the twelve months ended July 31, 2026, compared to $12.8 million in the year ago period. The year over year increase was primarily attributable to a $13.4 million increase in Cyclo's research and development expenses in fiscal 2026, as well as an increase in R&D stock-based compensation expense of $0.4 million, offset by decreases in R&D payroll of $1.5 million, and in clinical trial and other expenses of $0.8 million.

General and administrative expenses were $9.7 million for the twelve months ended July 31, 2026, compared to $13.8 million in the year ago period. The decrease of $4.1 million versus the prior year is primarily attributable to decreases in professional fees of $1.3 million, primarily due to merger-related costs in the prior year, stock-based compensation expense of $1.2 million, payroll expense of $0.6 million due to terminations, and other expenses.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is remibetadex (Trappsol® Cyclo™), for which we have completed a pivotal Phase 3 study in Niemann-Pick Disease Type C ("NPC") and submitted an NDA to the FDA in October 2026. NPC is a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the FDA's review of our NDA for remibetadex, including whether it will be accepted for filing, granted priority review or approved; our eligibility for and ability to monetize a priority review voucher; plans regarding the further evaluation of clinical data; and the potential of our pipeline. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risk that the FDA may not accept for filing or approve our NDA, including because the Phase 3 TransportNPC™ study did not meet its primary endpoint in the overall population, our need for additional financing and the substantial doubt about our ability to continue as a going concern, and those disclosed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2026, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Prompts

Rafael Holdings, Inc. (ticker RFL), listed in United States.

ETFs Holding Rafael Holdings, Inc.

ETF Weight in ETF Shares Market value As of
DXUV 0.00% 23,959 $ 26.594K Nov 12, 2026
DFAS 0.00% 44,769 $ 49.694K Nov 12, 2026
DCOR 0.00% 19,697 $ 21.864K Nov 12, 2026
DFAC 0.00% 36,442 $ 40.451K Nov 12, 2026
DFUS 0.00% 922 $ 1,023.42 Nov 12, 2026